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ABSTRACT
Background: An asthma-specific questionnaire, the Asthma Health Questionnaire (AHQ) was developed for
Japanese asthmatic patients. A self-administered 37-item version (AHQ-37) consisting of 36 disease-specific
items and a Face Scale was designed for socially active patients.
Methods: Exploratory factor analysis, test-retest reliability, internal consistency, concurrent validity and longi-
tudinal validity were evaluated. A total of 326 asthma patients (202 men ; range of age from 18 to 65 years) an-
swered the AHQ-37 twice.
Results: Each item of the AHQ-37 was well accepted by the patients with answering rates of 95 to 100%. Six
subscales (Asthmatic Symptoms, Emotion, Daily Activity, Factors which Worsened Symptoms, Social Activity
and Economics) were extracted by factor analysis. Psychometric testing showed high feasibility, good repeat-
ability and good internal consistency. The Face Scale moderately correlated with all subscales except for Eco-
nomics, indicating that the Face Scale alone could measure global quality of life (QOL) functioning of asthmatic
patients. Concurrent validity with peak-flow values was insufficient (Spearman’s correlation coefficient = 0.05―
0.27), showing that the peak flow alone could not estimate QOL. In longitudinal validity, however, changes in
peak-flow values had an impact on the Asthmatic Symptoms, Daily Activity and Factors which Worsened
Symptoms (P = 0.000―0.419), indicating that changes in peak-flow were important to asthmatic patients’ QOL.
Conclusions: The QOL of asthmatic patients must be evaluated by asthma-specific questionnaires, such as
the AHQ-37.
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INTRODUCTION
Adult asthma is a chronic inflammatory disease of the
airway 1-3 that involves long-term treatment and
follow-up.4-6 Within the past decade, new guidelines
for diagnosis and treatment of adult asthma have
been formulated in many countries and inhaled corti-
costeroids have been shown to be very effective for
control of symptoms.7-9 To evaluate the effectiveness
of the treatments, symptoms10 and peak flow value
were assessed. However, because many patients are
relatively young and socially active, the influences of
the disease and its treatment on daily life can be
great. In assessing the effectiveness of treatment and
the health status of asthmatic patients, quality of life
(QOL) should be evaluated11-13 in addition to symp-
toms10 and peak-flow value.14
Recently, health related quality of life (HRQOL) is
a much-discussed issue, and now, many researchers
evaluate patients’ HRQOL by a general illness ques-
tionnaire and a disease-specific module. In measuring
QOL of people who are active in their daily lives ,
culture-specific issues must be considered, such as
the differences between Japanese customs and cul-
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Fig. 1　Patients choose one of the 10 faces which is considered to express their own QOL best.
1 2 3 4 5 6 7 8 9 10
tures and those of English-speaking countries. Instru-
ments to measure QOL of asthmatic patients such as
the Asthma Quality of Life Questionnaire (AQLQ) by
Juniper et al. were developed and well validated in
Western countries . 15-19 There have been some re-
ports from Japan using international questionnaires
in the field of respiratory disease. 20-25 However , al-
though internal consistency and clinical validity were
reported, the reliability and validity of the question-
naire for Japanese were not fully investigated. There-
fore the cross-cultural validity of such imported ques-
tionnaires remains unclear. At the beginning of this
study, Japanese researchers had no tools to measure
QOL of asthmatic patients．
In the field of cancer, there have been two streams
in the development of QOL questionnaires in Japan ;
the development of Japanese versions of international
questionnaires, which were cross-culturally validated
using Japanese patients with target diseases26,27 on
the one hand, and the original development of ques-
tionnaires, such as the QOL Questionnaire for Can-
cer Patients Treated with Anticancer Drugs (QOL-
ACD),28,29 on the other. The standard procedures for
development of questionnaires were employed as re-
ported before, such as item collection from Japanese
patients, nurses, doctors and so on, extracting factors
and clinical validity analysis. The later method was
adopted because both the Japanese tongue and cul-
ture vastly differ from the English language and
Western culture. Cross-cultural validation and differ-
ences have been investigated meticulously in the de-
velopment of both imported questionnaires and Japa-
nese original questionnaires．
In the field of asthma, we considered that the same
methods, i.e., both importing international question-
naires and developing Japanese original question-
naires, were needed, because most asthmatic patients
are relatively young and socially active . The latter
was the aim of this study, namely to develop and vali-
date an asthma-specific questionnaire , the Asthma
Health Questionnaire (AHQ), using Japanese patients
with adult asthma．
METHODS
OVERVIEW
From October 1996 through January 2001, develop-
ment and validation of the AHQ took place in three
phases : (1) item generation, (2) pilot testing and (3)
estimation of reliability and validity. The procedures
in this study were in accordance with the Helsinki
Declaration (1964, amended in 1975 and 1983) of the
World Medical Association. Each phase will be pre-
sented in sequence．
Item Generation
The questionnaire was designed for patients 18 to 65
years of age and to be self-administered . Initially ,
items for the questionnaire were decided upon by dis-
cussion among four pulmonologists . The question-
naire was constructed from 26 items that could influ-
ence the daily life of patients. Thereafter, 62 Japanese
patients with asthma (28 male, 34 female ; age 20―65
years) who received care at the International Medical
Center of Japan (IMCJ) in Tokyo, 38 pulmonologists,
17 nurses and 7 psychiatrists discussed these items
and added 10 items. An initial questionnaire (37-item
version ) was constructed using 36 asthma-specific
items and a Face Scale30 (Fig. 1), which was the 37th
item. The Face Scale does not have a language bar-
rier and is easy to answer intuitively. Kurihara et al.
demonstrated that it expressed global QOL function-
ing. The asthma-specific items had 5 responses on
the Likert scale and the Face Scale had 10 responses.
Each item focused on the most recent week with
higher levels on each subscale representing worse
levels of QOL．
Pilot Testing
To measure the instrument’s comprehensibility and
acceptability, the 37-item version was pre-tested on 20
Japanese patients with asthma at the IMCJ. All pa-
tients were asked to complete the 37-item version and
then were interviewed to determine whether any
questions were difficult to comprehend andor were
not relevant to their QOL . Furthermore , patients
were asked to identify QOL issues that were not cov-
ered in the 37-item version. Specifically , qualitative
patient comments about item comprehension were
recorded. Information gathered during patient inter-
views was later considered in determining the final
version. As no inadequate items were identified, the
37-item version, the AHQ-37 (Appendix I), was inves-
tigated in terms of its reliability and validity．
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Appendix I
Asthma Health Questionnaire
This questionnaire is designed to find out how you have been feeling during the last week
Q1 I have a cough. 
Q2 I have phlegm.
Q3 I wheeze.
Q4 I have asthma atacks.
Q5 I get headaches.
Q6 I have shortness of breath.
Q7 My chest or shoulders feel heavy.
Q8 My chest feels tight.
Q9 I feel fatigued.
 Q10 My asthma keeps me awake at night.
 Q11 My asthma wakes me up in the morning.
 Q12 Exercise brings on asthma symptoms.
 Q13 Fatigue brings on asthma symptoms.
 Q14 Having a cold triggers my asthma.
 Q15 Inhaling substances like tobacco smoke, dust, cold air, exhaust fumes, polen, or cosmetics brings on asthma 
symptoms.
 Q16 Consuming certain food, alcohol, or non-asthma medications (fever-reducing medications, analgesics, etc.) brings on 
asthma symptoms.
 Q17 Contact with pets brings on asthma symptoms.
 Q18 Changes in the weather or atmospheric pressure bring on asthma symptoms.
 Q19 I feel depressed because I have asthma.
 Q20 I feel upset because I have asthma.
 Q21 I feel anxious because I have asthma.
 Q22 I feel iritable because I have asthma.
 Q23 My asthma makes it dificult for me to concentrate.
 Q24 My asthma prevents me from feeling refreshed.
 Q25 I am woried about having asthma.
 Q26 I am woried about having to continue taking asthma medication. 
 Q27 My emotional condition can make my asthma symptoms worse.
 Q28 My asthma symptoms limit my ability to walk.
 Q29 My asthma symptoms limit my ability to run or go uphil.
 Q30 My asthma symptoms limit my household activities, such as housework.
 Q31 My asthma symptoms limit my social and professional activities.
 Q32 My family has dificulties understanding my asthma problems.
 Q33 My coworkers, classmates and other people have dificulties understanding my asthma problems.
 Q34 I am reluctant to meet people who don’ tknow I have asthma.
 Q35 My asthmatic condition and it’ streatment are financialy burdensome.
 Q36 I am woried that my asthma is a burden to my family. 
 Q37 Considering the past 7 days, how is your overal of quality of life (QOL) ?
  Please choose one of the folowing faces which is considered to express your QOL best.
Response option: 0. not at al, 1. a litle bit, 2. somewhat, 3. quite a bit, 4. very much for items 1―36
Item 37: (Fig.1) 
RELIABILITY AND VALIDITY OF THE AHQ-37
Study Sample and Protocol
After informed consent had been obtained, the AHQ-
37 was administered to patients with asthma who
were treated at 15 cooperative institutes . These in-
struments were administered twice at an interval of 2
weeks. At the same time, patients wrote a diary re-
cording their asthmatic symptoms, peak flow values
and treatments. This diary was made by the Japanese
Society of Allergology, and is widely used in asthma
clinics in Japan . Patients recorded their asthmatic
symptoms using 5 responses according to the classifi-
cation of the Japanese Society of Allergology
(Fig. 2).31 A clinically meaningful change of peak flow
value was defined as a 10% change from the maxi-
mum baseline also according to the guidelines of the
Japanese Society of Allergology.
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Table 1 Patients’ Characteristics
(100.0%)n = 326Subjects
51.3 ± 14.9 years oldmean ± SE
Age
(10.1%)33<30
(15.6%)5130―39
(11.7%)3840―49
(29.1%)9550―59
(33.4%)10560―
(62.0%)202Male
Sex
(38.0%)124Female
4Inpatients
Inpatient/Outpatient
322Outpatients
(11.3%)37Improved
Change of symptoms＊
(61.3%)200Not Change
(14.7%)48Deterioration
(12.6%)41unknown
(11.3%)37Improved
Change of peak flow value＊＊
(57.7%)188Not Change
(9.2%)30Deterioration
(21.8%)71unknown
＊During two weeks, the changes of symptoms were recorded by a diary (see METHODS section). Improvement or deterioration of symp-
toms was recorded according to the classification of the Japanese Society of Alergology. 
＊＊During two weeks, the change of peak flow value was recorded. Improvement or deterioration was defined as a change of more than 
+10% or less than -10%, respectively, from baseline.
Fig. 2 The standard of the severity of asthmatic  symptoms. This classification is defined by the Japanese Society of 
Alergology.
1. The severity of symptoms
It is mainly diagnosed by “ Dyspnea” .
PEF (%)conciousnesscyanosisDaily activityconversationDyspneaThe severity of symptoms
unmeasurable
disturbed―
normal
+disabledificult
cannot move 
due to dysp-
nea
A major atack (severe)
less than 50%normal―dificult
slightly
dificult
cannot lay 
down due to 
dyspnea
B moderate atack (moderate)
50―70%normal―
slightly
dificult
almost
normal
can lay downC mild atack (mild)
more than 
70%
normal―
almost
normal
normalwheezeD1 wheeze
more than 
70%
normal―
almost
normal
normal
dyspnea on 
efort
D2 dyspnea
more than 
80%
normal―normalnormal―N asymptomatic
2. The severity of asthma
It is diagnosed by the combination of the severity of symptoms and the frequency.
DCBAfrequency severity
moderate2moderate1severesevere5―7days a week
mildmoderate2moderate1severe3―4days a week
mildmildmoderate1severe1―2days a week
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Table 2 Multitrait Scaling Analysis for AHQ: Convergent and Discriminant Validity
Evidence of item convergence validity was defined as a corelation above 0.4 (bold) of an item with it’ s own scale. In terms 
of item discriminant validity, a definite scaling eror was defined as corelation of an item with another scale that exceeded the 
corelation with its own scale.
Social Activity 
Factors which Worsened
Symptoms 
Daily ActivityEmotion
Asthmatic
Symptoms
0.3360.5150.3220.4050.645Q1
0.2420.4460.2830.3380.572Q2
0.3840.6280.4480.5670.761Q3
0.4520.5630.4240.5710.721Q4
0.3990.4600.3110.4700.497Q5
0.4710.6900.6070.6280.740Q6
0.4350.5730.4550.6010.645Q7
0.4190.6540.4950.6190.773Q8
0.4370.5650.4660.6100.724Q10
0.4490.6210.5060.5910.690Q11
0.4750.5950.4870.6000.654Q9
0.6100.6450.5930.8290.643Q19
0.5710.5980.5980.8160.651Q20
0.6260.6310.6030.8300.598Q21
0.6250.6350.5820.8300.652Q22
0.5760.6230.6280.8030.640Q23
0.5780.5760.6320.7870.644Q24
0.6300.5610.5110.7200.453Q25
0.5920.4820.4280.6020.394Q26
0.5050.5550.8230.6020.521Q28
0.5080.6170.7890.5760.472Q29
0.6060.6010.7580.6980.582Q30
0.5210.7210.6420.6070.672Q12
0.5500.7850.6370.6770.739Q13
0.4600.7390.5330.5790.686Q14
0.4460.7160.4820.5200.564Q15
0.3060.5370.3370.4170.409Q16
0.2690.4970.2300.3640.344Q17
0.4840.7350.5420.5860.610Q18
0.5890.6340.4870.6120.545Q27
0.5350.6130.7280.6640.542Q31
0.3760.2950.1820.3540.238Q32
0.5150.2980.2090.3590.253Q33
0.4900.4370.4970.5330.387Q34
0.5370.4850.4570.6240.441Q36
Psychometric Testing
The answering rate (feasibility) of the items on the
AHQ-37 at the initial and second measurements was
calculated. Using patients whose health status (symp-
toms and peak flow values written in the diary) had
not changed between the initial and second estima-
tion , weighted kappa coefficients of each item be-
tween the estimations were evaluated to investigate
test-retest reliability．
Factor analysis by Promax rotation were employed
to extract factors using the 36 asthma-specific items
on the AHQ-37. Then, the subscale structures of the
AHQ-37 were evaluated . Testing for item conver-
gence and discriminative validity was based on ex-
amination of the item-subscale correlation. Pearson’s
correlations of the item with its own subscale (cor-
rected for overlap) and with other subscales were cal-
culated. Evidence of item convergence validity was
defined as a correlation above 0.4 with its own
subscale. Item discriminant validity was supported by
a comparison of the magnitude of the correlation of
an item with its own subscale32 compared with other
subscales. A definite scaling error was defined as the
correlation of an item with another subscale that ex-
ceeded the correlation with its own subscale.
The internal consistency of each subscale was esti-
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The higher score of the AHQ-37 represents the worse level. Intraclass corelations was estimated by weighted kappa 
coeficients. Internal consistency was estimated by Cronbach’ s alpha coeficient. A value of 0.7 or greater was considered 
acceptable.
Cronbach’ salpha
Median 
(range)
Mean
(S.D.)
κ valueItemscale
0.8987.50
(0―100)
81.02
(19.1)
0.685Q1―8,10,11Asthmatic Symptoms (AS)
0.8888.88
(0―100)
82.29
(20.1)
0.895Q9,19―26Emotion (Em)
0.8991.66
(0―100)
82.33
(24.4)
0.868Q28―30Daily Activity (DA)
0.8984.37
(6.25―100)
77.33
(22.6)
0.840Q12―18,27Factors which Worsened Symptoms (FWS)
0.8985.00
(0―100)
81.43
(18.9)
0.865Q31―34,36Social Activity (SA)
―100
(0―100)
81.50
(28.0)
0.864Q35Economics (Ec)
―80.00
(10―100)
72.84
(22.1)
0.653Q37Face Scale (Global QOL)(FS)
Table 3 Mean, Median and Cronbach’ salpha and intra-class corelations (κ value) of the scales on the AHQ-37 
Table 4 Interscale corelation
It was hypothesized that a Pearson’ scorelation greater than 0.40 between scales infered that the two were conceptualy 
related.
AHQ-37
FSEcSAFWSDAEmAS
0.620.400.520.740.530.711.00Asthmatic Symptoms (AS)
0.600.460.710.720.671.00Emotion (Em)
0.480.330.600.631.00Daily Activity (DA)
0.540.430.601.00Factors which Worsened Symptoms (FWS)
0.470.591.00Social Activity (SA)
0.311.00Economics (Ec)
1.00Face Scale (Global QOL)(FS)
Table 5 Concurent Validity
The relationship between the scores of the AHQ-37 and the values of the symptom score and peak flow at the first measure-
ment was evaluated. Spearman’ scorelation coeficients were used to test the relationships.
CorelationSourceCorelationSourceValiables
AHQ-37
0.21PEF-0.54symptomAsthmatic Symptoms (AS)
0.13PEF-0.34symptomEmotion (Em)
0.27PEF-0.33symptomDaily Activity (DA)
0.27PEF-0.52symptomFactors which Worsened Symptoms (FWS)
0.09PEF-0.27symptomSocial Activity (SA)
0.05PEF-0.17symptomEconomics (Ec)
0.11PEF-0.40symptomFace Scale (Global QOL)(FS)
mated by Cronbach’s alpha coefficient. A value of 0.7
or greater was considered acceptable for group com-
parison . 33 Weighted kappa coefficients of each
subscale between the estimations were evaluated to
investigate subscale reliability. Construct validity was
estimated by correlations among the subscales com-
prising the AHQ-37. It was hypothesized that a Pear-
son’s correlation greater than 0.40 between subscales
inferred that the two were conceptually related.26
There was no gold standard instrument to estimate
the QOL of Japanese asthmatic patients. Thus, to esti-
mate concurrent validity, we evaluated the relation-
ship between the subscale scores of the AHQ-37 and
the symptom scores and peak flow values . Spear-
man’s correlation coefficients were used to test the
relationships. To evaluate clinical validity, longitudi-
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Table 6 Responsiveness
The changes in the AHQ-37 scores over time were examined in relationship to change in the symptom score and peak flow 
value.　Repeated-measures ANOVA was used to test inter-group diferences in scores over time of the AHQ-37.
P-Value
Delta value 
worsened 
no change 
improved
SourceP-Value
Delta value 
worsened 
no change 
improved
Source
AHQ-37
0.00599.7PEF<0.000114.9symptomAsthmatic
Symptoms (AS) 1.3 0.1
-2.1-8.5
0.50040.4PEF0.00062.5symptomEmotion (Em)
-0.9-1.1
-2.7-7.2
0.01316.7PEF0.0142 5.0symptomDaily Activity (DA)
-0.7-1.1
-1.30  
0.00966.6PEF<0.00017.7symptomFactors which Worsened
Symptoms (FWS) -1.4-1.3
-2.9-9.1
0.83320.9PEF0.36791.3symptomSocial Activity (SA) 
-0.1-0.3
-0.5-1.7
0.44423.0PEF0.1554-1.2symptomEconomics (Ec) 
-0.30.9
-1.6-4.8
0.33577.1PEF<0.000113.7symptomFace Scale (Global QOL) (FS) 
 2.30  
0  -2.7
nal validity was investigated. Changes in the AHQ-37
scores over time were examined in relation to
changes in symptom scores and peak flow values .
Repeated-measures ANOVA was used to test inter-
group differences in scores over time of the AHQ-37．
RESULTS
A total of 326 patients with adult asthma were stud-
ied. Their characteristics are shown in Table 1. Of the
326 patients, 202 were male and 124 were female ;
the mean age was 51 years (18―65 years). The feasi-
bility of items of the AHQ-37 ranged from 95 to 100%
at both the initial and second measurements, indicat-
ing that the AHQ-37 was well accepted by Japanese
patients with asthma . Using only patients whose
symptoms and peak-flow values were stable over 2
weeks, test-retest reliability was investigated by cal-
culating weighted kappa coefficients of each item be-
tween the two measures. All of the items of the AHQ-
37 were 0.5 or greater, indicating good repeatability．
From the 36 asthma-specific items on the AHQ-37,
an exploratory factor analysis extracted 6 factors :
Asthmatic Symptoms (10 items), Emotion (9 items),
Daily Activity (3 items) , Factors which Worsened
Symptoms (8 items), Social Activity (5 items) and
Economics (1 item). Multitrait scaling analysis con-
firmed adequacy in terms of item-convergent validity
for multi-item subscales on the AHQ-37 except for
one item (Table 2), Q32 :“My family has difficulties
understanding my asthma problems”. The other
items were well correlated (above 0.4) within their
own subscale, indicating satisfactory item-convergent
validity. In terms of item discriminant validity of the
AHQ-37, there were one and three problematic items
in the Emotion and the Social Activity subscales, re-
spectively ; the rate of scaling error was 5.7% (8
140)．
Cronbach’s Alpha coefficients for 5 multi-item
subscales in the AHQ-37 were 0.75 or greater (Table
3), indicating satisfactory internal consistency. Using
the stable patients above described, test-retest reli-
ability of the six subscales and the Face Scale was
also investigated by weighted kappa coefficients, and
satisfactory results were obtained (Table 3).34
In intersubscale correlations (Table 4), strong cor-
relations were observed in the relationships between
Asthmatic Symptoms and Factors which Worsened
Symptoms ( r = 0.74), between Emotion and Factors
which Worsened Symptoms ( r = 0.72), and between
Emotion and Social Activity ( r = 0.71), as expected.
Modest correlations were observed between each of
the subscales of the AHQ-37 except for Economics.
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The Economics subscale was not highly correlated
with the Daily Activity subscale (0.33) and the Face
Scale (0.31) of the AHQ-37. The Face Scale was mod-
erately correlated with all of the subscales of the
AHQ-37 ( 0.47 ― 0.62 ) except for the Economics
subscale (0.31)．
Concurrent validity with symptoms written in the
diary was supported by moderate correlations with
the Asthmatic Symptoms subscale (−0.54), Factors
which Worsened Symptoms subscale (−0.52), and the
Face Scale (−0.40) on the AHQ-37 (Table 5). How-
ever, correlation coefficients between the peak-flow
value and all the subscales of the AHQ-37 were low
(0.05 to 0.27)．
At the assessment made two weeks after the initial
assessment, symptoms had worsened in 48 patients,
improved in 37 patients and had not changed in 200
patients (Table 1). Repeated measures ANOVA was
employed to test for inter-group differences over time
in the AHQ-37 scores (Table 6). Responsiveness of
the AHQ-37 to changes in symptoms appeared to be
good except for the Social Activity and the Economics
subscales. At the second assessment, peak flow val-
ues had worsened in 30 patients, improved in 37 pa-
tients and had not changed in 188 patients (Table 1).
Repeated measures ANOVA showed that statistically
significant inter-group differences over time were ob-
served for Asthmatic Symptoms, Daily Activity, and
Factors which Worsened Symptoms on the AHQ-37
(Table 6).
DISCUSSION
Concurrent validity between the subscale scores on
the AHQ-37 and peak-flow values was insufficient ,
showing that the peak flow alone could not estimate
QOL (Table 5). The same situation was cited in other
reports. Juniper et al. reported that the correlation be-
tween peak-flow values and the subscales of the
AQLQ were weak or modest.19 This indicates the im-
portance of estimating the QOL of asthmatic patients
by self-administered, asthma-specific questionnaires．
The AHQ was developed for Japanese patients with
asthma in this study, and its 37 item version , the
AHQ-37, was found to have 6 subscales : Asthmatic
Symptoms, Emotion, Daily Activity , Factors which
Worsened Symptoms, Social Activity and Economics.
Psychometric testing showed that the AHQ-37 had
high feasibility, was easy to answer, and had good re-
peatability . However , multitrait scaling analysis
showed that only one item (Q32),“My family has diffi-
culties understanding my asthma problems”was in-
adequate with respect to item convergence (Table 2).
It may be considered to be reasonable that Q32 loads
on both Emotion and Social Activity. In terms of item
discriminancy, although the Social Activity subscale
had slightly weak structure , close relationships be-
tween this subscale and the other subscales may be
also reasonable. Cronbach’s alpha values for all the
multi-item subscales on the AHQ-37 indicated good
internal consistency．
The AHQ-37 had a unique item, the Face Scale
(Fig. 1).The Face Scale was developed by Lorish and
Maisiak.30 Kurihara et al. employed it in their ques-
tionnaire, the QOL-ACD, and the Face Scale moder-
ately correlated with all of the subscales on the QOL-
ACD, indicating that the Face Scale could be used to
estimate overall QOL functioning.28,29 This report led
us to consider whether the Face Scale could also be
used to express overall QOL of patients with asthma.
We found that this Face Scale moderately correlated
with all of the subscales of the AHQ-37 except for the
Economics subscale . This indicates that the Face
Scale could measure global QOL functioning of pa-
tients with asthma．
In concurrent validity, there were only modest cor-
relations between the scores of the Asthmatic Symp-
toms subscale, Factors which Worsened Symptoms
subscale and Face Scale on the AHQ-37, and the lev-
els of asthmatic symptoms cited using the diary (Ta-
ble 5). In longitudinal validity, however, changes in
symptoms affected the Asthmatic Symptoms, Emo-
tion , Daily Activity , and Factors which Worsened
Symptoms subscales, and the Face Scale on the AHQ
( P = 0.000−0.014)(Table 6). Although concurrent va-
lidity between the subscale scores on the AHQ-37
and peak-flow values was insufficient as mentioned
above (Table 5), changes in peak-flow values had an
impact on the Asthmatic Symptoms ( P = 0.0059) ,
Daily Activity ( P = 0.0131) and Factor which Wors-
ened Symptoms ( P = 0.0096) subscale (Table 6).
These indicated that changes in asthmatic symptoms
and peak-flow were important to asthmatic patients’
QOL．
The AHQ-37 has clinical validity, and is also reli-
able and valid for discriminative purposes, so it can
be used with confidence in clinical research. The next
step will be the validation of an imported question-
naire such as the AQLQ and comparison between the
imported questionnaire and the AHQ-37 in Japan .
This instrument has been translated into English
through rigid translationback translation procedures
(Appendix I ) . If the translated AHQ-37 could be
evaluated in English speaking cultures, cross-cultural
comparison would also become an interesting theme.
In conclusion, QOL of patients with asthma must be
measured by an asthma-specific module such as the
AHQ-37．
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